Literature DB >> 16141358

Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.

László Hunyady1, Kevin J Catt.   

Abstract

Angiotensin II (Ang II) activates a wide spectrum of signaling responses via the AT1 receptor (AT1R) that mediate its physiological control of blood pressure, thirst, and sodium balance and its diverse pathological actions in cardiovascular, renal, and other cell types. Ang II-induced AT1R activation via Gq/11 stimulates phospholipases A2, C, and D, and activates inositol trisphosphate/Ca2+ signaling, protein kinase C isoforms, and MAPKs, as well as several tyrosine kinases (Pyk2, Src, Tyk2, FAK), scaffold proteins (G protein-coupled receptor kinase-interacting protein 1, p130Cas, paxillin, vinculin), receptor tyrosine kinases, and the nuclear factor-kappaB pathway. The AT1R also signals via Gi/o and G11/12 and stimulates G protein-independent signaling pathways, such as beta-arrestin-mediated MAPK activation and the Jak/STAT. Alterations in homo- or heterodimerization of the AT1R may also contribute to its pathophysiological roles. Many of the deleterious actions of AT1R activation are initiated by locally generated, rather than circulating, Ang II and are concomitant with the harmful effects of aldosterone in the cardiovascular system. AT1R-mediated overproduction of reactive oxygen species has potent growth-promoting, proinflammatory, and profibrotic actions by exerting positive feedback effects that amplify its signaling in cardiovascular cells, leukocytes, and monocytes. In addition to its roles in cardiovascular and renal disease, agonist-induced activation of the AT1R also participates in the development of metabolic diseases and promotes tumor progression and metastasis through its growth-promoting and proangiogenic activities. The recognition of Ang II's pathogenic actions is leading to novel clinical applications of angiotensin-converting enzyme inhibitors and AT1R antagonists, in addition to their established therapeutic actions in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141358     DOI: 10.1210/me.2004-0536

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  169 in total

Review 1.  Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action.

Authors:  Pál Gyombolai; Dorottya Pap; Gábor Turu; Kevin J Catt; György Bagdy; László Hunyady
Journal:  Mol Cell Endocrinol       Date:  2011-11-02       Impact factor: 4.102

Review 2.  Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model.

Authors:  Julia L Cook; Richard N Re
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

3.  Deciphering biased-agonism complexity reveals a new active AT1 receptor entity.

Authors:  Aude Saulière; Morgane Bellot; Hervé Paris; Colette Denis; Frédéric Finana; Jonas T Hansen; Marie-Françoise Altié; Marie-Hélène Seguelas; Atul Pathak; Jakob L Hansen; Jean-Michel Sénard; Céline Galés
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

Review 4.  A 5'-upstream short open reading frame encoded peptide regulates angiotensin type 1a receptor production and signalling via the β-arrestin pathway.

Authors:  Gina L C Yosten; Jun Liu; Hong Ji; Kathryn Sandberg; Robert Speth; Willis K Samson
Journal:  J Physiol       Date:  2015-10-13       Impact factor: 5.182

Review 5.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

6.  S-Nitrosylation of β-Arrestins Biases Receptor Signaling and Confers Ligand Independence.

Authors:  Hiroki Hayashi; Douglas T Hess; Rongli Zhang; Keiki Sugi; Huiyun Gao; Bea L Tan; Dawn E Bowles; Carmelo A Milano; Mukesh K Jain; Walter J Koch; Jonathan S Stamler
Journal:  Mol Cell       Date:  2018-05-03       Impact factor: 17.970

7.  Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide.

Authors:  Jun Liu; Gina L C Yosten; Hong Ji; Dan Zhang; Wei Zheng; Robert C Speth; Willis K Samson; Kathryn Sandberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

8.  Leukocyte-dependent responses of the microvasculature to chronic angiotensin II exposure.

Authors:  Alper Yildirim; Janice Russell; Li-Sue S Yan; Elena Y Senchenkova; D Neil Granger
Journal:  Hypertension       Date:  2012-10-22       Impact factor: 10.190

9.  Structure-activity studies of RFamide-related peptide-1 identify a functional receptor antagonist and novel cardiac myocyte signaling pathway involved in contractile performance.

Authors:  Ruthann Nichols; Chloe Bass; Leslie Demers; Brian Larsen; Elton Li; Nathan Blewett; Kimber Converso-Baran; Mark W Russell; Margaret V Westfall
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

10.  A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation.

Authors:  Amee J George; Brooke W Purdue; Cathryn M Gould; Daniel W Thomas; Yanny Handoko; Hongwei Qian; Gregory A Quaife-Ryan; Kylie A Morgan; Kaylene J Simpson; Walter G Thomas; Ross D Hannan
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.